| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19,550 |
15,522 |
$1.39M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
7,761 |
7,192 |
$627K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,814 |
3,223 |
$377K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,737 |
2,940 |
$322K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,577 |
2,147 |
$87K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,678 |
1,373 |
$69K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,856 |
1,639 |
$51K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
277 |
266 |
$15K |
| 94750 |
|
288 |
204 |
$12K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
217 |
197 |
$9K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
367 |
302 |
$3K |
| 99215 |
Prolong outpt/office vis |
31 |
14 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
150 |
137 |
$2K |
| 94760 |
|
1,331 |
1,072 |
$2K |
| 81002 |
|
504 |
428 |
$1K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
71 |
71 |
$1K |
| 0224U |
|
110 |
96 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
60 |
46 |
$477.49 |
| 81025 |
|
39 |
36 |
$241.10 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
365 |
299 |
$34.19 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
13 |
12 |
$0.00 |